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Introduction {#sec004}
============

Since the global eradication of smallpox, the most important *Orthopoxvirus* infection in humans in terms of ongoing numbers of cases, morbidity, and mortality has been human monkeypox (MPX) \[[@pntd.0005857.ref001], [@pntd.0005857.ref002]\]. Monkeypox virus (MPXV) is maintained by an enzootic cycle, with zoonotic introductions to humans often being followed by more limited human-to-human transmission \[[@pntd.0005857.ref003], [@pntd.0005857.ref004]\]. The animal reservoir for MPXV remains unknown, but the virus has been isolated in the wild from a squirrel (*Funisciurus anerythrus*) and a sooty mangabey (*Cercocebus atys*) \[[@pntd.0005857.ref005], [@pntd.0005857.ref006]\].

Infection with MPXV can lead to a smallpox-like illness characterized by a febrile prodrome, lasting 1--4 days, followed by a slowly progressing rash. The rash proceeds from macules to papules to vesicles to pustules to crusts and finally to desquamation. This occurs over a period of two to four weeks. At any given site on the body, the rash is generally in the same stage of development (e.g., all vesicles), and the lesions are typically circumscribed, umbilicated, deep-seated and firm. The rash has a centrifugal distribution, with a concentration of lesions on the extremities and face. As with smallpox, MPX lesions often appear on the palms of the hands and soles of the feet. Lymphadenopathy (inguinal, axillary, and/or cervical) is common in MPX patients and can occur prior to or at the onset of rash. Ocular infection with MPXV can lead to permanent corneal scarring and blindness \[[@pntd.0005857.ref007]--[@pntd.0005857.ref009]\].

Infection with varicella zoster virus (VZV) has a similar presentation to that of MPXV infection, and in areas where MPXV is endemic these two illnesses are commonly mistaken \[[@pntd.0005857.ref010], [@pntd.0005857.ref011]\]. However, there are several features of illness that typically set one infection apart from the other. For example, VZV patients typically exhibit a short, mild period of febrile prodrome, or none at all, followed by a quickly evolving (1--2 day) pleomorphic rash (i.e., a rash for which neighboring lesions may be in different stages of development). VZV lesions also often have irregular borders, and are superficial on the surface of the skin (relative to those of MPX). In addition, varicella lesions often appear in a centripetal distribution on the body \[[@pntd.0005857.ref009], [@pntd.0005857.ref012]\]. Although noted in rare occurrences, lesions on the palms of the hands and soles of the feet are not hallmarks of VZV infections \[[@pntd.0005857.ref013]\]. VZV patients do not typically have pronounced lymphadenopathy, and, thus, the presence of lymphadenopathy is one distinguishing characteristic that can differentiate MPX from both smallpox and varicella. Additional illnesses that can be mistaken for MPX are other herpetic infections (in addition to VZV), drug eruptions, syphilis, yaws, scabies, and rickettsialpox \[[@pntd.0005857.ref009]\]. Specimen collection followed by laboratory testing can be difficult to accomplish for all suspected cases in MPX endemic areas. A clinical case definition capable of enhancing the distinction between MPX and other illnesses would be useful to enable more accurate and expedient case detection, collection of higher-quality surveillance data, and improved patient management.

MPXV is enzootic in western and central Africa, with the overwhelming majority of human infections reported each year from the forested areas of the Congo Basin of Democratic Republic of Congo (DRC) \[[@pntd.0005857.ref002]\]. MPX is a nationally reportable disease in DRC and has been identified as one of the country's priority diseases of epidemic potential. On a bi-weekly basis, notifications of suspected MPX cases from each of the country's Health Zones are submitted to national public health authorities; few of the suspected cases are formally investigated (i.e., case investigation forms completed and diagnostic specimens collected).

This study evaluates the diagnostic utility of two surveillance case definitions for MPX. Both definitions were herein applied to a cohort of suspected MPX cases that were identified over the course of a 42 month period via surveillance in one Province in DRC. This cohort is unique in that the dataset contained an in-depth list of signs/symptoms. The accuracy of case classification was determined using laboratory findings. We assessed clinical features of illness in patients with confirmed MPXV infection to identify characteristics distinctly associated with disease presentation and suggest modifications to the MPX surveillance case definition to improve specificity.

Methods {#sec005}
=======

Suspect case detection and laboratory classification {#sec006}
----------------------------------------------------

Data from suspect MPX cases were obtained by investigation in accordance with national guidelines. Patients were identified as suspect MPX cases if they had a vesicular or pustular eruption with deep-seated, firm pustules and at least one of the following symptoms: fever preceding the eruption, lymphadenopathy (inguinal, axillary, or cervical), and/or pustules or crusts on the palms of the hands or soles of the feet. For suspect cases, a MPX-specific case investigation form was completed and, in most instances, two or more diagnostic specimens were collected from each suspected MPX case. The specimens were sent to the Institut National de Recherche Biomédicale (INRB) in Kinshasa for diagnostic testing. One specimen from each individual was tested at INRB for the presence of *Orthopoxvirus* DNA signatures using a real-time PCR assay \[[@pntd.0005857.ref014]\]. If the initial PCR was negative for *Orthopoxvirus*, a second real-time PCR assay specific for VZV-specific DNA signatures was conducted (reagents provided by the United States Army Medical Research Institute of Infectious Diseases). DNA extracted at INRB and additional independent specimens, if available, were shipped to the Poxvirus Laboratory at the U.S. Centers for Disease Control and Prevention (CDC). At the CDC, DNA was extracted from original specimens and all specimens were tested with MPXV and VZV-specific real-time PCR assays \[[@pntd.0005857.ref015], [@pntd.0005857.ref016]\].

An individual was classified as a laboratory-confirmed MPX case if at least one specimen was 1) positive with the *Orthopoxvirus*-specific assay, and/or 2) positive by MPX-specific real-time PCR. An individual was independently classified as a laboratory-confirmed VZV case if a crust specimen tested positive for VZV DNA signatures at INRB or if an original vesicular swab or crust specimen tested positive for VZV at CDC.

Ethical statement {#sec007}
-----------------

These activities were determined to not be research by a CDC human subjects advisor.

Dataset and variable inclusion for analyses {#sec008}
-------------------------------------------

Suspect MPX cases in Tshuapa Province, DRC, with rash onset occurring between September 2009 and February 2014 were included in the analysis (N = 1025, [Fig 1](#pntd.0005857.g001){ref-type="fig"}). These individuals were all assessed by a surveillance officer, who determined the individual met the surveillance case definition for a suspect MPX case. Individuals whose laboratory test results were suggestive of a coinfection with both MPXV and VZV, and those with incomplete or inconsistent laboratory results were excluded from analyses (n = 273). A total of 752 cases were included for further analyses; 333 laboratory-confirmed MPX cases, 383 laboratory-confirmed VZV cases, and 36 cases that were determined to not be either MPX or VZV (laboratory diagnosis undetermined).

![Flow chart of the cases selected for each analysis.](pntd.0005857.g001){#pntd.0005857.g001}

Clinical signs and symptoms were recorded as checkboxes---'yes', 'no', and 'do not know'---on the case investigation form. If an individual case investigation form had a response ('yes or 'no') for any signs/symptoms, but the absence of a response for another specific sign/symptom the variable was coded as "missing" for the specific sign/symptom without a response. Febrile prodrome status was determined by either a) selection of 'yes/no' for the febrile prodrome variable on the case investigation form, or, if that information was missing, by, b) presence of prodrome was ascertained by determining the time interval between onset of fever and that of rash, when the information was available. The presence of lymphadenopathy was determined using the individual lymphadenopathy-type fields (inguinal, axillary, cervical). If at least one category of lymphadenopathy was reported as present, then the individual was coded "yes" for lymphadenopathy; if all fields were "no", the individual was coded "no" for lymphadenopathy. If one or more of the fields were missing and others were "no", the individual was coded "missing" for lymphadenopathy.

Two surveillance case definitions were evaluated in this study. According to Case Definition A, a suspect case is an individual with fever followed by a vesicular or pustular rash with the following symptoms: rash on palms, soles, and face; or the presence of 5 variola-like scars. Case Definition A has been recommended for use in endemic areas.

Case Definition B was developed as a discriminatory case definition with the inclusion of several criteria that distinguish MPX from VZV. Case Definition B encompasses individuals who have a vesicular or pustular eruption with deep-seated, firm pustules and at least one of the following symptoms: fever preceding the eruption, lymphadenopathy (inguinal, axillary, or cervical), and/or pustules or crusts on the palms of the hands or soles of the feet.

To evaluate the diagnostic accuracy of each case definition, the dataset was restricted to individuals who had all the information needed for classification using *both* case definitions (i.e., one dataset was used for the independent analyses of both definitions). A total of 645 of the 752 cases (85.8%) had sufficient information to be included in the analyses of both case definitions; 314 laboratory-confirmed MPX cases, 305 laboratory-confirmed VZV cases, and 26 cases that were determined to be neither MPX nor VZV ([Fig 1](#pntd.0005857.g001){ref-type="fig"}). Individuals met the criteria for Case Definition A if they had a febrile prodrome and either the presence of a) rash/scars on the face, palms, and soles, or b) more than 5 scars. Individuals met the criteria for Case Definition B if they had rash with deep-seated, firm lesions and either a) febrile prodrome, b) lymphadenopathy, or c) lesions on the palms of the hands or soles of the feet. This dataset was also used for the receiver operating characteristic analysis.

Statistical analysis {#sec009}
--------------------

The frequencies of each sign/symptom were calculated for all cases included in the dataset, and individually for laboratory-confirmed MPX and VZV cases. Associations between reported signs/symptoms and laboratory determined diagnoses were calculated using chi-squared and Fisher exact tests. Signs/symptoms that occurred with significantly different frequency (p\<0.05) between laboratory-confirmed MPX and VZV cases were further assessed for their individual sensitivity, specificity, PPV and NPV in relation to the confirmed diagnosis of MPX.

For the analysis of the two case definitions, real-time PCR diagnostic test results (for MPX and VZV) were used as the 'gold standard' to establish MPX and VZV diagnoses. The sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV) were computed for the two case definitions.

A receiver operating characteristic (ROC) analysis was completed using 'fever before rash' and various summed frequencies of the 12 signs/symptoms that were identified as having high (\>80%) sensitivities or specificities for laboratory-confirmed MPX cases. For example, individuals with 'fever plus rash' and one of these 12 signs/symptoms were categorized as having '1 criteria'; individuals with 'fever plus rash' and 12 signs/symptoms were ranked as '12 criteria'. Each of these 12 signs/symptoms counted equally to the sum. For example, if an individual reported two symptoms of 'nausea' and 'cough', they were categorized the same as an individual who reported two symptoms of 'fatigue' and 'conjunctivitis'. 'Fever before rash' was identified as a mandatory sign/symptom because this has been consistently noted in the literature for MPX patients and also was observed at a frequency of 98.1% for all suspect cases and 99.1% for laboratory-confirmed MPX patients in the present analysis. The sensitivity, specificity, PPV and NPV for each model (with increasing number of signs and symptoms from 1 to 12) were assessed.

All data analysis was performed using SAS version 9.3.

Results {#sec010}
=======

Characteristics of the Population: A total of 752 suspect cases were included in the analysis. Approximately 53% of suspect cases were male and 46% were female; this proportion remained consistent after laboratory case classification. The mean age of suspect cases was 17 years (median 13, range 0.01--86). Of these suspect cases, 333 (44.3%) individuals were classified as laboratory-confirmed MPX cases and 419 (55.7%) were classified as laboratory-confirmed VZV (383) or undiagnosed (36) cases ([Table 1](#pntd.0005857.t001){ref-type="table"}).

10.1371/journal.pntd.0005857.t001

###### Characteristics of suspect monkeypox (MPX) cases identified between December 2009 and February 2014 (n = 752).

![](pntd.0005857.t001){#pntd.0005857.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                               Total          Laboratory-confirmed MPX cases   Laboratory-confirmed VZV   Undiagnosed cases[^a^](#t001fn001){ref-type="table-fn"}
  -------------------------------------------- -------------- -------------------------------- -------------------------- ---------------------------------------------------------
  All suspect cases                            752 (100%)     333 (44.3%)                      383 (50.9%)                36 (4.8%)

  Sex[^b^](#t001fn002){ref-type="table-fn"}\   \              \                                \                          \
   Male\                                       397 (52.9%)\   178 (53.4%)\                     205 (53.5%)\               14 (38.9%)\
   Female\                                     349 (46.4%)\   154 (46.2%)\                     174 (45.4%)\               21 (58.3%)\
   Missing                                     6 (0.8%)       1 (0.3%)                         4 (1.0%)                   1 (2.8%)

  Age (years)\                                 \              \                                \                          \
   Mean\                                       17.04\         5.77\                            18.15\                     16.98\
   Median\                                     13.33\         13.82\                           13\                        14.72\
   Range\                                      0.01--86\      0.08--67\                        0.01--86\                  0.8--46\
   Missing                                     3              n/a                              2                          1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Undiagnosed cases are those that were determined to not be either MPX or VZV.

^b^ Percentages for sex are within column percentages

Performance of specific clinical characteristics: With the objective of improving the specificity and PPV of the case definitions under examination, associations between the reported clinical signs/symptoms and a laboratory-confirmed diagnosis of MPX (versus VZV) were investigated. Significant (p\<0.05) differences between laboratory-confirmed MPX and VZV cases were noted for the signs/symptoms of nausea, cough, lymphadenopathy (overall and each site), mouth ulcers, sore throat, malaise, fatigue, conjunctivitis, sensitivity to light, and bedridden ([Table 2](#pntd.0005857.t002){ref-type="table"}). Rash characteristics that were significantly different included same size, deep-seated, firm lesions, and the presence of lesions on the arms, legs, palms of the hands, soles of the feet, and genitals. Each of the significant signs/symptoms and rash characteristics occurred more frequently in laboratory-confirmed MPX cases than in laboratory-confirmed VZV cases. The majority of significant signs/symptoms (15/20) occurred in more than 50% in laboratory-confirmed MPX cases.

10.1371/journal.pntd.0005857.t002

###### Association between clinical characteristics and laboratory-confirmed monkeypox (MPX) or varicella (VZV) case classification.

![](pntd.0005857.t002){#pntd.0005857.t002g}

  Sign or Symptom         All suspect cases (752)   Laboratory-confirmed MPX cases (333)   Laboratory-confirmed VZV cases (383)   p-value[^a^](#t002fn001){ref-type="table-fn"}                                     
  ----------------------- ------------------------- -------------------------------------- -------------------------------------- ----------------------------------------------- ----- ------- ----- ----- ------- --------------
  Fever                   732                       737                                    99.3%                                  329                                             329   100%    371   376   98.7%   0.0644
  Rash                    718                       750                                    95.7%                                  316                                             332   95.2%   367   382   96.1%   0.5594
  Febrile Prodrome        727                       741                                    98.1%                                  327                                             330   99.1%   371   379   97.9%   0.1965
  Nausea                  140                       737                                    19.0%                                  75                                              328   22.9%   58    374   15.5%   **0.0131**
  Cough                   347                       744                                    46.6%                                  192                                             331   58.0%   135   378   35.7%   **\<0.0001**
  Lymphadenopathy         562                       731                                    76.9%                                  277                                             325   85.2%   265   371   71.4%   **\<0.0001**
   Axillary               369                       737                                    50.1%                                  191                                             327   58.4%   166   375   44.3%   **0.0002**
   Cervical               416                       736                                    56.5%                                  206                                             326   63.2%   195   375   52.0%   **0.0028**
   Inguinal               323                       738                                    43.8%                                  168                                             326   51.5%   142   377   37.7%   **0.0002**
  Chills                  593                       744                                    79.7%                                  262                                             328   79.9%   302   381   79.3%   0.8400
  Mouth ulcers            333                       741                                    44.9%                                  190                                             326   58.3%   131   381   34.4%   **\<0.0001**
  Sore Throat             451                       738                                    61.1%                                  246                                             325   75.7%   188   378   49.7%   **\<0.0001**
  Headache                548                       729                                    75.2%                                  243                                             322   75.5%   283   373   75.9%   0.9011
  Pruritis                379                       734                                    51.6%                                  170                                             321   53.0%   196   378   51.9%   0.7701
  Malaise                 453                       720                                    62.9%                                  228                                             319   71.5%   211   367   57.5%   **0.0001**
  Fatigue                 590                       740                                    79.7%                                  278                                             328   84.8%   286   377   75.9%   **0.0032**
  Conjunctivitis          126                       739                                    17.1%                                  79                                              328   24.1%   43    377   11.4%   **\<0.0001**
  Sensitivity to light    198                       729                                    27.2%                                  105                                             323   32.5%   86    372   23.1%   **0.0057**
  Bedridden               137                       743                                    18.4%                                  95                                              327   29.1%   41    381   10.8%   **\<0.0001**
  Rash characteristics                                                                                                                                                                                              
   Monomorphic            573                       658                                    87.1%                                  286                                             319   89.7%   264   312   84.6%   0.0585
   Same size              581                       657                                    88.4%                                  291                                             319   91.2%   264   311   84.9%   **0.0063**
   Deep-seated and firm   621                       660                                    94.1%                                  310                                             319   97.2%   286   314   91.1%   **0.0011**
  Rash site                                                                                                                                                                                                         
   Face                   736                       743                                    99.1%                                  330                                             333   99.1%   372   375   99.2%   0.8838
   Thorax                 723                       743                                    97.3%                                  328                                             333   98.5%   362   375   96.5%   0.0973
   Arms                   704                       742                                    94.9%                                  326                                             332   98.2%   345   375   92.0%   **0.0002**
   Legs                   331                       352                                    94.0%                                  191                                             197   97.0%   125   138   90.6%   **0.013**
   Palms                  677                       742                                    91.2%                                  324                                             333   97.3%   319   374   85.3%   **\<0.0001**
   Soles                  604                       743                                    81.3%                                  309                                             333   92.8%   264   375   70.4%   **\<0.0001**
   Genitals               144                       692                                    20.8%                                  87                                              309   28.2%   52    349   14.9%   **\<0.0001**

^a^ Chi-square test between laboratory-confirmed MPX and VZV cases. Significant p-values (p\<0.05) are in bold.

^b^ n is the number of cases reported to have the sign/symptom and N is the total number of cases with data present.

Variables with high sensitivity for MPX (≥80%) were lymphadenopathy, fatigue, and the following rash characteristics: same size, deep-seated firm lesions, presence on the arms, legs, palms of the hands, and soles of the feet ([Table 3](#pntd.0005857.t003){ref-type="table"}). Nausea, conjunctivitis, bedridden, and lesions present on the genitals were signs/symptoms with a high specificity (≥80%), but none of these, individually, were found in laboratory-confirmed MPX cases at a frequency \> 32%.

10.1371/journal.pntd.0005857.t003

###### Diagnostic measures[^a^](#t003fn001){ref-type="table-fn"} of significant[^b^](#t003fn002){ref-type="table-fn"} clinical signs/symptoms.
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  Symptom                 Sensitivity[^c^](#t003fn003){ref-type="table-fn"}   Specificity[^c^](#t003fn003){ref-type="table-fn"}   PPV                     NPV
  ----------------------- --------------------------------------------------- --------------------------------------------------- ----------------------- ---------------------------
  Nausea                  22.87% (18.32--27.41)                               **84.11% (80.56--87.65)**                           53.57% (45.31--61.83)   57.62% (53.66--61.59)
  Cough                   58.01% (52.69--63.32)                               62.47% (57.80--67.14)                               55.33% (50.1--60.56)    64.99% (60.30--69.68)
  Lymphadenopathy         **85.23% (81.37--89.09)**                           29.80% (25.35--34.25)                               49.29% (45.15--53.42)   71.60% (64.80--78.40)
   Axillary               58.41% (53.07--63.75)                               56.59% (51.79--61.38)                               51.76% (46.66--56.86)   63.04% (58.11--67.98)
   Cervical               63.19% (57.95--68.43)                               48.78% (43.94--53.62)                               49.52% (44.71--54.32)   62.50% (57.20--67.80)
   Inguinal               51.53% (46.11--56.96)                               62.38% (57.70--67.06)                               52.01% (46.56--57.46)   61.93% (57.26--66.60)
  Mouth ulcers            58.28% (52.93--63.63)                               65.54% (60.97--70.11)                               57.06% (51.74--62.37)   66.67% (62.09--71.24)
  Sore Throat             75.69% (71.03--80.36)                               50.36% (45.54--55.19)                               54.55% (49.95--59.14)   72.47% (67.31--77.64)
  Malaise                 71.47% (66.52--76.43)                               43.89% (39.03--48.75)                               50.33% (45.73--54.94)   65.92% (60.23--71.60)
  Fatigue                 **84.76% (80.87--88.65)**                           24.27% (20.13--28.41)                               47.12% (43.09--51.15)   66.67% (59.12--74.21)
  Conjunctivitis          24.09% (19.46--28.71)                               **88.56% (85.49--91.64)**                           62.70% (54.25--71.14)   59.38% (55.49--63.27)
  Sensitivity to light    32.51% (27.4--37.62)                                77.09% (73.01--81.18)                               53.03% (46.08--59.98)   58.95% (54.76--63.13)
  Bedridden               29.05% (24.13--33.97)                               **89.90% (87.01--92.8)**                            69.34% (61.62--77.06)   61.72% (57.85--65.59)
  Rash characteristics                                                                                                                                    
   Same size              **91.85% (88.85--94.85)**                           14.79% (11.01--18.58)                               50.43% (46.36--54.50)   65.79% (55.12--76.46)
   Deep-seated and firm   **97.18% (95.36--99.00)**                           8.80% (5.79--11.80)                                 49.92% (45.99--53.85)   76.92% (63.70--90.15)
  Rash site                                                                                                                                               
   Arms                   **98.19% (96.76--99.63)**                           7.80% (5.21--10.40)                                 46.31% (42.62--49.99)   **84.21% (72.62--95.80)**
   Legs                   **96.95% (94.55--99.35)**                           9.68% (5.02--14.33)                                 57.70% (52.38--63.03)   71.43% (52.11--90.75)
   Palms                  **97.30% (95.56--99.04)**                           13.69% (10.36--17.02)                               47.86% (44.10--51.62)   **86.15% (77.76--94.55)**
   Soles                  **92.79% (90.02--95.57)**                           28.05% (23.70--32.40)                               51.16% (47.17--55.15)   **82.73% (76.45--89.02)**
   Genitals               28.16% (23.14--33.17)                               **84.86% (81.27--88.45)**                           60.00% (52.03--67.97)   59.41% (55.30--63.53)

^a^ Each diagnostic measure is presented with the 95% confidence interval.

^b^ Significant clinical characteristics were chosen from a comparison of laboratory-confirmed MPX and VZV cases, [Table 2](#pntd.0005857.t002){ref-type="table"}.

^c^ Diagnostic measures with values ≥80% are in bold.

Analysis of the case definitions: Two-by-two tables and diagnostic values for the two case definitions are presented in Tables [4](#pntd.0005857.t004){ref-type="table"} and [5](#pntd.0005857.t005){ref-type="table"}. Two hundred ninety-one (92.6%) laboratory-confirmed MPX cases satisfied Case Definition A; and 306 (97.5%) laboratory-confirmed MPX cases satisfied Case Definition B; 245 (74%) and 303 (91.5%) non-MPX cases \[laboratory-confirmed VZV cases and undiagnosed (MPX and VZV negative) cases\] satisfied Case Definitions A and B, respectively.

10.1371/journal.pntd.0005857.t004

###### The number of suspect monkeypox (MPX) cases that were captured by Case Definitions A and B by their MPX laboratory case classification.
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  Laboratory- confirmed MPX Case [^a^](#t004fn001){ref-type="table-fn"}   Case Definition A   Case Definition B                    
  ----------------------------------------------------------------------- ------------------- ------------------- ----- ----- ---- -----
  Yes                                                                     291                 23                  314   306   8    314
  No                                                                      245                 86                  331   303   28   331
  Total                                                                   536                 109                 645   609   36   645

^a^ MPX case classification determined by laboratory test results.

10.1371/journal.pntd.0005857.t005

###### Summary of the diagnostic parameters for both case definitions.
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  Parameter     Case Definition A[^a^](#t005fn001){ref-type="table-fn"}   Case Definition B[^a^](#t005fn001){ref-type="table-fn"}
  ------------- --------------------------------------------------------- ---------------------------------------------------------
  Sensitivity   92.68% (89.79--95.56)                                     97.45% (95.71--99.20)
  Specificity   25.98% (21.26--30.71)                                     8.46% (5.46--11.46)
  PPV           54.29% (50.07--58.51)                                     50.25% (46.28--54.22)
  NPV           78.90% (71.24--86.56)                                     77.78% (64.20--91.36)

^a^ % (95% confidence interval)

The sensitivity of both case definitions was high, with the value for the Case Definition B a bit higher than that of Case Definition A (97.45% vs. 92.86%, respectively). Similarly, the specificity of both case definitions was low and the Case Definition A had a higher specificity (25.98%) than Case Definition B (8.46%). The PPVs were similar for both definitions (50.25% for Case Definition B and 54.92% for Case Definition A), as were the NPVs (77.78% for Case Definition B and 78.90% for Case Definition A). The NPV was higher than the PPV for both definitions.

Receiver operating characteristic analysis: Using the 12 identified signs/symptoms with high sensitivity and/or specificity values, the ROC analysis tested the performance and accuracy of 12 models (with increasing numbers of signs and symptoms) ([Table 6](#pntd.0005857.t006){ref-type="table"}). In general, models with a greater number of signs/symptoms (\>8 but \<12) demonstrated excellent specificity (\>90%) but low sensitivity (\<40%). In contrast, models with a lower number of signs/symptoms (\<7) had excellent sensitivity (\>90%) but low specificity (\<40%). The models for MPX cases that had the presence of 'fever before rash' plus at least 7 or 8 of the 12 signs/symptoms demonstrated a more balanced performance between sensitivity and specificity. There was greatly improved specificity for the models that included 7 (50.76%) or 8 (70.69%) signs/symptoms when compared to either Case Definition A (25.98%) or B (8.46%). The area under the curve for the model using these summed symptom counts was 0.74 ([Fig 2](#pntd.0005857.g002){ref-type="fig"}).

10.1371/journal.pntd.0005857.t006

###### Accuracy of the minimum number of signs/symptoms in predicting laboratory-confirmed monkeypox cases.
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  No. signs/ symptoms[^a^](#t006fn001){ref-type="table-fn"}   1        2        3        4        5        6        7        8        9        10       11       12
  ----------------------------------------------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------
  **Sensitivity**                                             100%     99.68%   99.04%   98.09%   94.59%   90.13%   81.85%   66.88%   36.94%   13.38%   3.18%    0%
  **Specificity**                                             0.30%    0.60%    1.81%    5.74%    15.41%   32.33%   50.76%   70.69%   91.84%   98.49%   99.09%   100%
  **PPV**                                                     48.76%   48.75%   48.90%   49.68%   51.47%   55.82%   61.19%   68.40%   81.12%   89.36%   76.92%   \-\--
  **NPV**                                                     51.24%   51.25%   51.10%   50.32%   48.53%   44.18%   38.81%   31.60%   18.88%   10.64%   23.08%   \-\--

^a^ Sum of the minimum number of highly sensitive or highly specific signs/symptoms present for a suspect monkeypox case that also had 'fever before rash'

![A receiver operating characteristic analysis showing the area under the curve for the model using the symptom 'fever before rash' and various summed frequencies of 12 signs/symptoms.](pntd.0005857.g002){#pntd.0005857.g002}

Discussion {#sec011}
==========

The choice and utility of a case definition will be guided by its intended use. Case Definition A was designed to detect a single case of MPX illness, followed by an immediate outbreak response and control efforts. Case Definition B was designed to be a discriminatory definition used in the context of surveillance for disease, to better understand the extent and burden of disease in an endemic area. Both case definitions were characterized by high sensitivities but very low specificities. The high values for sensitivity were expected since the dataset represented patients who were diagnosed with suspected MPX virus infection (prior to laboratory confirmation). These characteristics indicate that both definitions are useful for screening purposes and are well-designed for outbreak detection. Given that MPX is an endemic, regularly occurring, reportable disease in Tshuapa Province, the case definitions should be sufficient to capture true MPX cases, such that local or national officials may want to launch an outbreak response if they observe an aberration or threshold in the number or rate of reported infections. For surveillance purposes, however, especially in resource-limited countries such as DRC, it is necessary for a definition to capture all true cases and at the same time minimize the number of false positives. Attributes of Case Definition B, including a low specificity and moderate PPV, are not optimal for the objectives of disease surveillance. Observations of a moderate PPV and high NPV for both case definitions is consistent with a disease with a low prevalence in the population. Although prominent and regularly occurring, MPX does have a relatively low incidence in Tshuapa Province with a cumulative incidence rate of 4.8/10,000 over a four year period (data available upon request).

Several signs/symptoms had a high sensitivity (lymphadenopathy, fatigue, and the following rash characteristics: same size, deep-seated firm lesions, presence on the arms, legs, palms of the hands, and soles of the feet), which indicates that these signs/symptoms may be useful in ruling out other febrile rash illnesses that may be circulating in an area of active MPXV transmission. Signs/symptoms with a high specificity (nausea, conjunctivitis, bedridden, lesions present on the genitals), on the other hand, may be useful in identifying true MPX cases. These four signs/symptoms and, also, sensitivity to light were characteristics that occurred more frequently in laboratory-confirmed MPX cases than VZV cases. However, none of these discriminatory signs/symptoms were found at a high frequency in MPX cases (\<50%). Thus, these signs/symptoms may be eligible components of a case definition to identify MPX cases, however, they cannot be a mandatory component.

Case definitions for MPX include characteristics of disease presentation specific to the rash itself. This analysis reinforced the inclusion of lesion size and surface presentation (deep-seated vs superficial). Notably, the "characteristic" lesion locations of palms of the hands and soles of the feet, although present in higher frequency in MPX cases than VZV cases, were prevalent in all suspect cases (91.2% and 81.3%, respectively) and were not helpful in increasing the specificity for MPX cases. Lesions on the palms and soles have been previously noted in VZV cases in central Africa \[[@pntd.0005857.ref013]\], and the findings here indicate that this presentation may be more common than recognized before.

The benefit of an ROC analysis is that one is able to evaluate the effect of increasing number of signs and symptoms on the sensitivity and specificity of case identification. Both laboratory-confirmed MPX and VZV cases presented with many of the same signs and symptoms. Instead of limiting the case definition to an all-or-nothing analysis, we chose to limit the ROC analysis to a subset of highly sensitive and specific signs/symptoms. As such, the analysis indicated that the combination of 7 or 8 signs/symptoms was the most optimal model to accurately predict laboratory-confirmed MPX cases. This analysis emphasized the utility of including the minimum 12 signs/symptoms (nausea, conjunctivitis, bedridden, lesions on genitals, lymphadenopathy, fatigue, lesions of the same size, deep-seated firm lesions, lesions present on the arms, legs, palms of the hands, or soles of the feet) on a MPX-specific case investigation, followed by the classification of a patient as a suspect MPX case if they possessed a combination of any 7 or 8 of these specific signs/symptoms plus 'fever before rash'. Suspected MPX patients are rarely followed over the course of their infection. Patients are often only seen once, the data on clinical signs/symptoms is assessed and captured at that single time point, and no further follow-up is conducted. A definition such as the one suggested by the ROC analysis may allow for greater flexibility and utility in detecting true MPX cases at any given point during the course of the infection, since it allows for the presence of 7 or 8 signs/symptoms (versus 12). Additional evaluations to discern a specific suite of signs/symptoms that can be easily identified by healthcare personnel in endemic areas are warranted. This could be followed by modification of the surveillance investigation tool to incorporate the 12 signs/symptoms and evaluation of the utility of a new, modified case definition that accounts for the presence of 7 or 8 signs/symptoms when determining if a patient is a suspected MPX case.

The population used in this analysis was a population of suspect MPX cases identified through surveillance for human MPX illness in DRC. A total of 137 cases were excluded from the final analysis due to incomplete data from case report forms (missing signs/symptoms). The majority of excluded cases were laboratory-confirmed VZV cases (78 or 72.9% of those excluded), which may lead to a slight bias in the dataset that contains relatively more laboratory-confirmed MPX cases than were identified in the surveillance dataset. However, a similar proportion of laboratory-confirmed MPX and VZV cases were used for the analyses. Further, data from the suspect MPX cases was collected at one point in time during their illness. The dataset is unique in that it captured many signs/symptoms present for patient; similar datasets with a large number of patients/cases are not available for independent comparison. This data does not represent the spectrum of signs/symptoms that a patient may experience over the course of their illness, and, the result may be a limitation in the frequency of signs/symptoms for suspect cases. Nevertheless, this data reflected the range of presentations of signs/symptoms recognized in suspected MPX patients in an area with endemic disease.

In order to document and detect endemic human MPX cases, a surveillance case definition with more specificity in accurate case detection is needed. In rural DRC there are increasingly limited resources, competing health priorities, and a lack of regional testing capacity, which emphasizes the need to easily and efficiently deploy a case definition to accurately identify true MPX patients and limit false positives. A single MPX case or the decision to launch an outbreak response requires considerable resources. According to national guidelines, once a MPX case is identified, the case should be isolated and contacts should be followed for 21 days. Strict recommendations regarding hygiene and infection control are instituted for the entire period of illness, which can last for four weeks. In the absence of a more specific case definition, continued emphasis on laboratory-based diagnostics is warranted. More rapid and efficient methods of diagnosing suspect MPX patients, via a regional surveillance laboratory or a clinical laboratory, are needed to better identify and care for patients followed by appropriate control measures.
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